Currently submitted to: JMIR Research Protocols
Date Submitted: Aug 11, 2026
Open Peer Review Period: Aug 12, 2026 - Oct 7, 2026
(closed for review but you can still tweet)
NOTE: This is an unreviewed Preprint
Warning: This is a unreviewed preprint (What is a preprint?). Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn (a note "no longer under consideration" will appear above).
Peer review me: Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period (in this case, a "Peer Review Me" button to sign up as reviewer is displayed above). All preprints currently open for review are listed here. Outside of the formal open peer-review period we encourage you to tweet about the preprint.
Citation: Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).
Final version: If our system detects a final peer-reviewed "version of record" (VoR) published in any journal, a link to that VoR will appear below. Readers are then encourage to cite the VoR instead of this preprint.
Settings: If you are the author, you can login and change the preprint display settings, but the preprint URL/DOI is supposed to be stable and citable, so it should not be removed once posted.
Submit: To post your own preprint, simply submit to any JMIR journal, and choose the appropriate settings to expose your submitted version as preprint.
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Optimizing Home-Based Auricular Vagus Nerve Stimulation for Pain, Function, and Inflammation in Veterans with Knee Osteoarthritis: Protocol for a Randomized Pilot Dose-Finding Study
ABSTRACT
Background:
Knee osteoarthritis (KOA) is a leading cause of pain and disability among Veterans. Current nonsurgical treatments primarily target peripheral inflammation, often providing incomplete symptom relief. Transcutaneous auricular vagus nerve stimulation (taVNS) is a nonpharmacologic neuromodulation therapy with the potential to modulate both inflammatory and central pain pathways. However, the optimal dosing regimen and biologic effects of home-based taVNS in KOA remain unknown.
Objective:
This study aims to identify the optimal home-based taVNS dosing regimen by comparing improvements in pain and physical function between high-dose taVNS, low-dose taVNS, and corticosteroid injection (CSI), while also evaluating dose-dependent changes in inflammatory biomarkers in Veterans with KOA.
Methods:
This prospective, open-label, randomized, 3-arm pilot clinical trial will enroll 40 Veterans with symptomatic KOA from the Atlanta Veterans Affairs Health Care System. Participants will be randomized in a 3:3:2 allocation to receive high-dose taVNS (n=15), low-dose taVNS (n=15), or a single intra-articular CSI (n=10). Clinical outcomes will be assessed using the Pain, Enjoyment of Life and General Activity scale (PEG-3); Defense and Veterans Pain Rating Scale (DVPRS); Knee Injury and Osteoarthritis Outcome Score (KOOS), Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function, and the Central Sensitization Inventory. Peripheral blood samples will be collected to evaluate changes in inflammatory biomarkers. The primary outcomes are changes in PEG-3 and DVPRS scores and inflammatory biomarker concentrations following treatment.
Results:
At the time of manuscript submission, Emory Institutional Review Board approval has been obtained (Protocol # 2026P000226), though ClinicalTrials.gov registration is pending, and participant recruitment is yet to begin. Following trial registration, participant enrollment and data collection will proceed according to the study protocol.
Conclusions:
This pilot trial will provide preliminary evidence regarding the clinical and biologic effects of home-based taVNS in Veterans with KOA and identify an optimal dosing regimen for future clinical trials. If successful, the findings may support the development of a home-based, nonpharmacologic treatment strategy targeting both inflammatory and central pain mechanisms in KOA. Clinical Trial: ClinicalTrials.gov (registration pending)
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.